



Willingness to take Antiretroviral Drugs in a high HIV prevalence Setting: the case of adults living in Chawama township of Lusaka, Zambia



Munthali C. Sharon^{1,2}, Charles Michelo¹

¹ Department of community medicine, University of Zambia, Lusaka, Zambia

² Cancer Diseases Hospital, P. O Box 51337RW Lusaka, Zambia

Address of Correspondence

Sharon Chongo Munthal, Department of Community Medicine, University of Zambia
P.O. Box 50110, Lusaka, Zambia | Tel: +260-977-872483 | E-mail: scmunthali@yahoo.com

<https://doi.org/10.53974/unza.jabs.6.1.873>

ABSTRACT

Background: The willingness to take antiretroviral drugs (ARVs) has been found to be associated with several factors. We investigated the level of willingness to take antiretroviral drugs and factors likely to be associated with willingness among adults living in Chawama township.

Methods: This was a cross-sectional study of 409 adult respondents aged 18 years and above, recruited by a simple random sampling method. A structured questionnaire was used to collect socio-demographic data and other factors likely to influence willingness. Determinants of willingness and association between variables of interest were examined using multivariate analysis.

Results: about 52.8% of females and 46.9% of males participated in the study. The mean age of participants was 31

years (SD±11.60). The response rate was 99%. A high level of willingness was observed, with more than 50% of participants willing to take ARVs if they were found legible for ART. Some of the key factors that were found significantly associated with willingness were the aspect of being male or female, with females being more likely to be willing than males, the perceived effectiveness of ARVs, the need for consent to begin ARV treatment with females being more likely to needing consent than men, and fear of discrimination.

Conclusion: There is a high willingness to take antiretroviral drugs among community members suggesting a high potential to influence individual acceptability and general uptake of ARVs. Furthermore, stigmatizing attitudes and socio-cultural influences towards people taking ARVs persist and interventions to reduce these influences are needed.

Keywords: Willingness, Antiretrovirals, HIV, ART, Adults, Zambia

INTRODUCTION

HIV/AIDS has continued to be a global pandemic disease affecting millions of lives. The disease burden has decreased in recent years due to Antiretroviral Therapy (ART), Prevention of Mother to Child Transmission (PMTCT) and other intervention programmes. However, despite the deployment of free ART in most settings, there is still resistance to taking ARVs, adherence and HIV testing (11).

Prevention of the development of HIV into full-blown AIDS and death using ARVs is the cornerstone of HIV/AIDS management. Considerable expansion of the ART programme, which has occurred rapidly in Zambia, needs to be accompanied by community awareness campaigns and education if acceptance, uptake and adherence are to be enhanced. Perceived unwillingness to take ARVs may influence future unwillingness to take up ART. This study, therefore, explored factors influencing community willingness to participate in ART. There is limited literature or study findings on willingness to take ARVs among adults in the Zambian general community.

With the rapid scale-up of HIV care and treatment, there is a need to determine why certain patients do not want to go on treatment and why others drop out of treatment. Amongst the various factors influencing willingness to take ARVs are; competing remedies to ARVs, such as traditional medicine, religious and socio-cultural influences, economic challenges and service-related factors (32). Community perception and acceptability of ARVs greatly influence uptake and enrollment in ART programmes. In a study conducted in South Africa on critical barriers to community participation in HIV and antiretroviral services, poverty, socioeconomic factors

and stigma were found to be significant barriers to accessing HIV and AIDS care and treatment services in the public health sector (23).

METHODS

Population and sampling procedures

The study population comprised one adult 18 years and above at each selected household in the area. The target age group was 18 years and above. The size of the population from which the sample was calculated was 1200 households. The sample size (409) was calculated using the statistical package EP Info version 6. According to the Lusaka City Council mapping, Chawama township was divided into 21 household zones. All the 21 zones were purposively selected, followed by a probability proportional to the size selection of a representative number of households in each zone. The households were simple randomly selected. Only one eligible adult was selected for each selected household. A simple random sample selection was employed in selected households with more than one consenting adult.

Data collection and analysis

A structured questionnaire was used to collect information in a face-to-face interview with only one eligible and willing household member living in the area. Information on socio-cultural, demographics, knowledge of ARVs, and perceptions of ARVs was obtained. The Statistical Package for the Social Sciences (SPSS) version 17 for Windows was used for overall analysis.

Multivariate logistic regression analysis was used to determine adjusted odds ratios for all independent factors associated with willingness to take ARVs.

The logistic regression results were only adjusted for sex, giving results on two key variables, the need for consent and fear of discrimination by both sexes. The Chi-square test was used to determine the association between variables of interest.

Ethical consideration

Ethical clearance was granted by the University of Zambia Research and Ethics committee, and the Lusaka City Council Chawama Site Office granted written permission to conduct the study. All participants gave written consent for participation. Client names were not included on questionnaires, and information submitted was treated with strict confidentiality except for the purpose of the study.

RESULTS

Participation and distribution

Of the total participants (n=409), 216 (52.8%) were females and [192(46.9%)] were males. The age range was 18 to above 50 years, with many participants [156 (38.1%)] being 18-24. The mean age was 31 years (SD±11.60), with the majority having gone up to secondary school [217(53.1%)].

Few participants had attained tertiary education [23(5.6%)] and the unemployed comprised the majority of participants [287 (70%)]. None of the demographic factors were associated with willingness (Pv >0.5). The rest of the demographic findings are described in table 1.

Other key findings were that 33.3% of respondents expressed that they would need consent or permission from their partners or family members before beginning ARV treatment. While 51.6% (211) expressed fear of discrimination or stigma by their family members if they were found taking ARVs, 73.8% (302) believed that ARVs were effective.

Other descriptive findings of the study are illustrated in Table 1. Table 2 in the annex shows the associations observed between the various factors and willingness. An association was observed between a belief in ARVs effectiveness and willingness to take ARVs, P<0.0001. Participants willing to take ARVs because they perceived ARVs were effective were 265 (65%) and were more than those who perceived ARVs to be non-effective. An association also existed between those who perceived they could manage to take ARVs for life with willingness (p<0.0001). The place of preference for treatment was observed to have an association with willingness (p<0.0001), with 317(77.4%) willing to access treatment from the clinic and not any other place. The need to get consent from family or partner had an association with willingness, p<0.0001, with those needing no consent but willing being the majority [212 (52.1%)]. The fear of being discriminated against by a partner or family when one opted to take ARVs was associated with willingness to take ARVs (p<0.0001).

Determinants of willingness using regression analysis

Sex was the only demographic factor that was observed significantly influencing willingness, with females [176(43.1%)] being 2.27 more likely to be willing to take ARVs than males [AOR: 2.27(95%CI, 1.10 -4.70)].

Participants [265 (65.3%)] who perceived that ARVs were effective were 3.50 more likely to be willing to take ARVs than those who said they were not effective [AOR: 3.50(1.71 - 7.82)].

Other factors that were included in the model are illustrated in table 3a.

When the regression analysis was adjusted for sex, males that believed they needed no consent were 77% less likely

to be willing than those that believed they needed consent. The females that believed they needed no consent were 1.22 more likely to be willing to take ARVs than those that believed they needed consent. Findings for males on discrimination were not significant [AOR: 1.47, (95% CI, 1.15-1.89)]. However, they were significantly high for females, with those that lacked fear of discrimination being 2.70 more likely to be willing than those that believed they would be discriminated against (Table 3b).

DISCUSSION

The key findings to be discussed in this section are; a high level of willingness, a high level of perceived effectiveness of ARVs, the need for consent to begin ARV treatment and fear of discrimination.

The study revealed that more than 50% (83%) of participants were willing to take ARVs, with females being more likely to be willing to take ARVs than males. This result was not surprising, especially in the African setup where the HIV/AIDS disease burden weighs more on women than males (37). It was not also surprising to observe the presence of more females than males at the time of the study. This could be attributed to the observed social-cultural influences in the country, such as early marriages and the idea that women should be keepers of the home (4). High willingness could also be attributed to a high turn-up of participants due to high unemployment levels.

The study revealed that the perception of the effectiveness of ARVs had a significant contribution to the willingness of participants to take ARVs. Those who had a belief that ARVs were effective were more likely to be willing to take ARVs than those who said they were not. The high level of willingness due to

believing that ARVs were effective could be attributed to the longevity, a new life, and hope these drugs have provided for people living with HIV/AIDS within the community (4). Therefore, knowing that ARVs were effective had a positive influence on willingness.

The study demonstrated that despite high levels of HIV awareness, stigma and discrimination were still being perpetuated in the community. Discrimination was found to significantly influence females' willingness to take ARVs more than it did influence the males. These findings are consistent with other research findings that have also shown that discrimination is common, especially against women in most African settings. Reports have shown that other persons, particularly women, may be beaten by their partners if they disclose their HIV status and may be refused to seek treatment (13).

The study findings revealed that females were more likely to need consent to begin ARV treatment than males. Reports have also shown that in most households, females tend to seek consent much more than males for various reasons for decision-making. Many cultural factors such as religious stigma; domestic violence; socioeconomic constraints, including literacy, living conditions, nutrition, presence or absence of family etc., have been found to affect treatment and individual acceptability of treatment with ARVs (34).

The high level of unemployment (70%) observed among participants reflected the typical situation in Zambia, where the majority of people (>70%) are unemployed. (3) Despite high unemployment levels, most participants were willing to take ARVs. There was also overwhelming acceptance of ARVs as a long-life treatment and that the clinic was the preferred place of treatment.

CONCLUSION

The willingness to take ARVs was found to be relatively high among adults living in Chawama, an urban community. Willingness to take ARVs is a very essential element to getting more people on ART and thereby contributes to the reduction of morbidity and mortality due to HIV/AIDS. However, some of the findings presented in this study raise many policy issues and research challenges. As revealed by the study, stigma or discrimination is still being perpetuated in some communities; increased sensitization programmes are required on the reality of ARVs and HIV/AIDSs.

Although the HIV/AIDS burden weighs more on women than males in Africa, community programs involving both males and females should be encouraged to promote a willingness and a positive attitude towards ARVs, especially among males who showed less willingness in this study.

ARVs perceived effectiveness should be reinforced by effectively monitoring the manufacturing and supply processes of these drugs. Poor quality ARVs should not be supplied in the country as this promotes inefficiencies in managing HIV/AIDS with ARVs. Poor quality ARVs have been associated with unknown side effects and low efficacy, leading to poor patient management and a low willingness to take ARVs. Illiteracy levels are high in the country, and thus, a deliberate move to provide educational materials on ARVs in local languages should be made. This may improve knowledge of ARVs. A good understanding of what drugs or medications one is taking increases the likelihood of taking such medications. Notwithstanding the fact that HIV/AIDS has been in existence for the past

20/30 years, now discrimination against PLWHA is still being perpetuated in many communities. There is, therefore, a challenge to ascertain the level of this discrimination.

Study Limitations

The study design (cross-sectional) does not provide the cause and effect of the findings. The study findings were therefore limited to Chawama township only. Willingness could have been well measured over a large population coverage. However, a small area was considered due to limited time, and a tiny sample size was selected, one adult per household. Focus groups and individual discussions were not conducted in this study due to limited resources and time.

ACKNOWLEDGEMENT

My sincere gratitude to Dr C Michelo (Supervisor) and Dr W Mutale (Co-supervisor) for their valuable contributions and support, and many thanks to the Ministry of Health for their financial support.

REFERENCES

1. *Badri et al (2004)*. An assessment of the revised World Health Organization scaling-up guidelines AIDS Journal: Vol 18(8) 1159-1168.
2. Baylor International Pediatric AIDS Initiative (BIPAI) (2006). *HIV Curriculum for the Health Professional*. Baylor College of Medicine.
3. Central Statistical Office (CSO) (2007). Zambia Demographic Health Survey- Preliminary Report. Government Printers.

4. Central Statistical Office (CSO) (2003). Zambia Demographic Health Survey. Government Printers.
5. Central Statistical Office (CSO) (1999). Zambia Sexual Behavior Survey 1998 Ministry of Health, Measure Evaluation. Lusaka, Zambia. Government Printers.
6. Chitambo (2007) Living with Hope - African Churches and HIV/AIDS. World Council of Churches, Geneva. Switzerland.
7. Dilger H et al (2009). Prolonging Life, Challenging Religion. Justo Mwale College, Lusaka Zambia.
8. Gomani P et al (2006) Acceptance of antiretroviral therapy among patients infected with HIV and Tuberculosis in Rural Malawi is low and associated with Cost of Transport. The International Journal of Tuberculosis and Lung Diseases, 9(3) 238-47.
9. The British Columbia Centre for Excellence in HIV/ AIDS (2004), 15th International Conference on AIDS. Bangkok, Vancouver, Canada.
10. Lusaka City Council (LCC) (2007). A Report on the Status of Unplanned Settlements in Lusaka. Government Printers.
11. Mathew P Fox, A Mazimba et al (2010). Barriers To Initiation Of Antiretroviral Treatment In Rural And Urban Areas Of Zambia: A Cross-Sectional Study Of Cost, Stigma, and Perceptions About ART. Journal Of The International AIDS Society.
12. MOH (2008). Multi-sectoral AIDS Response Monitoring and Evaluation Biennial Report 2006-2007. Government Printers.
13. MOH b (2008). Management of Adult HIV with Antiretroviral Therapy. A Reference Manual for Health Workers. Government Printers.
14. MOH (2007). ARVs, HIV and VCT. Annual Health Statistical Bulletin 2006, November, pp.24 Government Printers.
15. MOH b (2007). 2007 Antiretroviral Therapy Protocols. Pocket Guide Government Printers
16. MOH (2006). Scale – UP Plan. HIV Care and Antiretroviral Therapy Services 2006 – 2008. Government Printers.
17. MOH (2005). Towards Attainment of the Millennium Development Goals, and National Health Priorities, HIV/AIDS and STI. National Health Strategic Plan 2006-2010, November. Government Printers.
18. MOH b (2005). National HIV/AIDS/STI/TB Policy. Lusaka Zambia, Government Printers.
19. Montgomery ET *et al* (2004). Factors influencing VCT Uptake & ART acceptance for Zimbabwean Antenatal Women. International Conference on AIDS Bangkok, Thailand abstract no. TuPeD5182. UZ-UCSF, Harare, Zimbabwe.
20. National Aids Council and MOH (2010). Monitoring the Declaration of Commitment on HIV/AIDS and the Universal Access. Zambia Country Report Lusaka, Government printers.
21. National Aids Council (2004). Joint Review of the National HIV/AIDS/STI/TB Intervention Strategic Plan (2002-2005) and Operations of the National AIDS Council. Lusaka, Government printers.
22. National AIDS Council (2008). HIV and AIDS in Zambia. <http://www.avert.org/aids-zambia.ht>

23. Padarath et al (2006). Community Participation in HIV and ARV services Journal of South African Health Review pp: 95-104.
24. Rutaremwa G (2004). Individual attitudes, perceptions and beliefs toward HIV/AIDS care, prevention and control in Uganda: cross-sectional evidence from Uganda. International Conference on AIDS (15th: 2004: Bangkok, Thailand). Abstract no. TuPeD5189. Makerere University, Kampala, Uganda.
25. Schumaker L and Bond V (2008). Antiretroviral therapy in Zambia: Colors, ‘Spoiling, ‘Talk’ and the meaning of Antiretrovirals. An International Journal of Social Science and Medicine. Elsevier Ltd.
26. Siulanda N (2007). HIV/AIDS- In search of a cure- ARVs Vs Herbal Remedies. Health and Wellness. Panorama Journal.
27. Tsiko S (2004) ARVs Bring New Hope. The Journal of Health Systems Trust <http://www.hst.org.za/news/20040417>.
28. UNAIDS (1998). Gender and HIV/AIDS [http:// whqlibdoc.who.int/unaid/1998/gender_HIV_eng.pdf](http://whqlibdoc.who.int/unaid/1998/gender_HIV_eng.pdf).
29. WHO (2008). Statistics. <http://www.who.int/countries/zmb/en/>
30. WHO/AFRO (2007). WHO Statement on treatment of HIV/AIDS. PRESS RELEASE.
31. WHO (2006). Adherence Research. World Health Organization Collaborating Center on Pharmaceutical Policy.
32. WHO (2003). Fact sheet 134. Traditional Medicine.
33. WHO/AFRO (2001). Traditional Medicines Show ‘Encouraging Results’ In Management Of HIV/AIDS. PRESS RELEASE.
34. Willard S & Angelino A (2008). The Need for Socio-cultural Awareness to Maximize Treatment Acceptance and Adherence in Individuals Initiating HIV Therapy. Journal of the International Association of physicians in AIDS cure.
35. Shannon K, Bright V, et al (2004) Uptake and acceptance of antiretroviral medications among female sex workers. Vancouver’s downtown eastside.
36. UNAIDS (2008). Report on the global AIDS Epidemic. UNAIDS Geneva.
37. UNAIDS (1998). Guidance Modules on Antiretroviral Treatments.
38. Zuumond M (2008). CAFOD- Adherence to ARVs- Challenges and Success A Consultation with CAFOD Partners and Members of the Catholic HIV/AIDS Network (CHAN). Research Report.

Table 2: Association of factors with willingness using the Chi-square test

Factor		Participants willing to take ARVS	Total Participants (n)	P value
Age:	<21	16.9%	79	
	21-30	35.8%	174	
	31-40	17.6%	87	
	40-51	7.8%	40	
	>50	4.9%	28	
Sex:	Male	40.0%	192	0.22
	Female	43.1%	216	
Marital status:	Single	40.0%	203	0.86
	Married	43.1%	205	
Education:	Not educated	35.5%	169	0.14
	Educated	47.5%	239	
Occupation	Unemployed	59.6%	286	0.08
	Employed	23.5%	122	
Perceived effectiveness of ARVs:	Non-effective	18.0%	104	<0.0001
	Effective	65.3%	302	
Perceived acceptance of lifelong treatment:	No	7.9%	53	<0.0001
	Yes	78.1	354	
Preferred place of treatment:	Other	5.9%	54	<0.0001
	Clinic	77.4%	353	
Religion:	Other	1.5%	8	0.41
	Christians	81.5%	397	
Denomination:	Catholic	16.2%	79	0.35
	Other	66.8%	316	
Needing consent to begin ARV:	No	52.1%	271	<0.0001
	Yes	31.2%	136	
Discrimination:	Yes	36.4%	196	<0.0001
	No	46.9%	211	
Knowledge:	Inadequate	44.2%	212	0.50
	Adequate	39.0%	193	

Table 3a: Logistic regression results on willingness to take ARVs

Independent Factors		Prevalence (total %)	Univariate OR(95%CI)	Multivariate OR(95%CI)
Age	18-20	64(15.7%)	1.32(0.67-2.6)	1.44(0.56-3.69)
	20-35	186(45.6%)	1.20(0.50-2.88)	0.50(0.15-1.72)
	36-45	51(12.5%)	0.81(0.34-1.94)	0.54(0.17-1.70)
	46>	38(9.3%)	1	1
Sex*	Male	163(40%)	1	1
	Female	176(43.1%)	0.78(0.46-1.32)	2.27(1.10- 4.70)
Marital Status	Single	163(40%)	1	1
	Married	1764(43.1)	1.49(0.88-2.51)	0.70(0.34- 1.42)
Education	Not educated	145(35.5%)	1	1
	Educated	194(47.%)	0.71(0.42-1.23)	1.11(0.54- 2.32)
Occupation	Unemployed	243(59.6%)	1	1
	Employed	96(23.5%)	1.53(0.89-2.63)	1.98(0.93 - 4.20)
Perceived RV Effectiveness*	Non-effective	73(18%)	1	1
	Effective	265(65.3%)	3.04(1.77-5.24)	3.50(1.71 - 7.82)
Preferred place of treatment*	Other	24(5.9%)	1	1
	Clinic	315(77.4%)	10.36(5.50-19.52)	5.37(2.37-12.01)
Perceived acceptance of Lifelong treatment*	No	21(5.2%)	1	1
	Yes	318(78.1%)	13.46(7.03-25.77)	8.16(3.51-18.97)
Needing consent to begin ARV treatment*	Yes	212(52.1%)	1	1
	No	127(31.2%)	3.92(1.88-8.19)	1.30(1.20 – 2.72)
Fear of Discrimination*	Yes	148(36.4%)	1	1
	No	191(46.9%)	3.10(1.762-5.444)	2.47(1.22- 5.00)
Knowledge on ARVs*	Inadequate	179(44.2%)	1	1
	Adequate	158(39.0%)	0.83(0.49 – 1.40)	2.23(1.07 – 4.64)

*Denotes significant factors

Table 3b: Showing regression analysis on needing consent and fear of discrimination adjusted for sex

	Males			Females	
		Prevalence (%n)	AOR (95%CI)	Prevalence (%n)	AOR (95%CI)
Needing consent to begin ARV treatment:	Yes	30.9%(n=62)	1	50.0%(n=142)	1
	No	54.5%(n=129)	0.23(0.48-0.82)	31.5%(n=74)	1.22(1.88-2.50)
Fear of discrimination:	Yes	36.6%(n=90)	1	36.1%(n=106)	1
	No	48.7%(n=101)	1.47(1.15-1.89)	45.4%(n=110)	2.70(1.05-6.97)